This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at bakerdan@wsu.edu.
Single use vials (preservative-free); single use prefilled syringes (preservative-free); multiple use vials (preservative) 2 mg/0.5 mL, 1 mg/0.5 mL, 3 mg/0.5 mL, 4 mg/0.5 mL, 5 mg/0.5 mL, 6 mg/0.5 mL, 10 mg/mL, 20 mg/2 mL Not all strengths are available for each dosage form.
Product labeling: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202799s000lbl.pdf Additional efficacy information was requested to support its use for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Ridaforolimus
Taltorvic (Merck / Ariad Pharmaceuticals)
Voted 13 to 1 against approval as maintenance therapy for patients with metastatic soft-tissue sarcoma or bone sarcoma whose disease has not progressed after at least four cycles of chemotherapy (continued) Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue the drug as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy.
(continued) Life-threatening cardiac dysrhythmias and/or sudden death have occurred in patients using methadone.
PRECAUTIONS Drug Interactions
Calcium channel blockers: A clinical study showed that felodipine exposure was increased by coadministration of itraconazole, resulting in approximately a 6-fold increase in the area under the curve and an 8-fold increase in the peak concentrations. The concomitant use of itraconazole and felodipine is contraindicated.
ADVERSE REACTIONS Postmarketing Experience
Dyspnea and acute generalized exanthematous pustulosis http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm223891.htm Lenalidomide Revlimid (Celgene Corporation)
WARNINGS AND PRECAUTIONS Second Primary Malignancies
Patients with multiple myeloma treated with lenalidomide in studies including melphalan and stem cell transplantation had a higher incidence of second primary malignancies, particularly acute myelogenous leukemia (AML) and Hodgkin lymphoma, compared to patients in the control arms who received similar therapy but did not receive lenalidomide. WARNINGS AND PRECAUTIONS When saxagliptin was used in combination with a sulfonylurea or with insulin, medications known to cause hypoglycemia, the incidence of confirmed hypoglycemia was increased over that of placebo used in combination with a sulfonylurea or with insulin. Therefore, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia when used in combination with saxagliptin-containing products. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm283038.htm
Sitagliptin products
Janumet & Januvia (Merck)
WARNINGS AND PRECAUTIONS Hypersensitivity Reactions
Angioedema has also been reported with other dipeptidyl peptidase-4 (DPP-4) inhibitors. Use caution in patients with a history of angioedema with another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with sitagliptin. 
WARNINGS AND PRECAUTIONS Atypical subtrochanteric and diaphyseal femoral fractures
Atypical subtrochanteric and diaphyseal femoral fractures have been reported in patients receiving bisphosphonate therapy. These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to just above the supracondylar flare and are transverse or short oblique in orientation without evidence of comminution. These fractures occur after minimal or no trauma. Patients may experience thigh or groin pain weeks to months before presenting with a completed femoral fracture. ADVERSE REACTIONS Postmarketing Experience Atypical subtrochanteric and diaphyseal femoral fractures Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm244411.htm a Practitioners are encouraged to check the FDA's MEDWATCH Web site (http://www.fda.gov/medwatch/safety.htm) for updated information.
